Join us at ESGCT 2025 in Sevilla for an important presentation by Jean-Philippe Combal from Vivet Therapeutics on October 9th at 10:00am CET during the session entitled  Immune responses to gene therapy. https://lnkd.in/enSxNwzF
Learn how VTX-PID (imlifidase) enables optimal depletion of anti-AAV3B neutralizing antibodies in human subjects, expanding eligibility for future systemic AAV-based gene therapies through innovative dose-ranging and PK/PD modeling approaches.
With sincere thanks from the Vivet Therapeutics Team and our Co-Founder, Gloria Gonzalez-Aseguinolaza González Aseguinolaza